publication venue for
- Epidemiology of systemic vasculitis.. 37:113-120. 2024
- Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology.. 36:113-119. 2023
- Blood and urine biomarkers in osteoarthritis - an update on cartilage associated type II collagen and aggrecan markers.. 34:54-60. 2022
- The role of immunomodulatory medications in the treatment of COVID-19.. 33:431-445. 2021
- Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.. 33:292-299. 2021
- Osteoporosis and fractures in rheumatoid arthritis.. 33:270-276. 2021
- Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities?. 32:297-306. 2020
- An update on the role of epigenetics in systemic vasculitis.. 30:4-15. 2018
- Targeting aging for disease modification in osteoarthritis.. 30:101-107. 2018
- Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.. 29:277-284. 2017
- Aging processes and the development of osteoarthritis.. 25:108-13. 2013
- Aging and osteoarthritis.. 23:492-6. 2011
- Cardiovascular disease in rheumatoid arthritis: a step forward.. 22:342-7. 2010
- Mitogen-activated protein kinases as therapeutic targets in osteoarthritis.. 20:581-6. 2008
- Transgenic mouse models of metabolic bone disease.. 13:316-25. 2001
- Benefits and promotion of physical activity in rheumatoid arthritis. 2020
- Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities? 2020